A patent infringement lawsuit filed against Occlutech CEO Tor Peters by St. Jude is "amazing and quite shocking," according to Peters.
A patent spat between St. Jude Medical (NYSE:STJ) and Occlutech GmbH that morphed into a personal lawsuit against Occlutech CEO Tor Peters was dismissed by a German court, prompting Peters to call the suit "amazing and quite shocking."
St. Jude inherited the case, involving intravascular occlusion devices, after it acquired AGA Medical for more than $1 billion last year.
Anthem Blue Cross Blue Shield
, Argentum Medical
, Ethicon Endo-Surgery
, HemCon Medical Technologies Inc.
, ICU Medical Inc.
, Johnson & Johnson
, Marine Polymer Technologies Inc.
, Noble Biomaterials
, Occlutech GmbH
, RyMed Technologies Inc.
, St. Jude Medical
, Zynex Inc.
Lawsuits accusing C.R. Bard of selling defective and dangerous transvaginal mesh products are piling up, with the latest batch seeking to join a consolidated federal case.
Dozens of patients with lawsuits against C.R. Bard Inc. (NYSE:BCR) asked to join a multi-district federal case against the company for allegedly selling defective and dangerous products – its Avaulta transvaginal mesh.
In one of the most recent suits, Lois Houghton wants a jury to decide whether Bard was negligent in designing the product and whether it failed to warn patients and doctors of potential risks.
Avedro Inc. appoints med tech veteran C. Evan Ballantyne as its chief financial officer.
Waltham, Mass.-based medical device and pharmaceutical company Avedro appointed industry veteran C. Evan Ballantyne as its new chief financial officer.
Prior to the appointment, Ballantyne was the VP & CFO of biopharmaceutical company Clinical Data Inc., chief financial officer of Beverly, Mass.-based ZymeQuest, and vice president at chief operating officer at the ACNielsen Corporation.
The top three medical device stories for September 26, 2011.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com's coverage highlights our three biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with Massdevice +3.
A federal judge in Texas shoots down a bid by Covidien to stop Applied Medical Resources from making surgical trocars in a long-running patent dispute, because neither company still makes the devices.
A federal judge in Texas "has a hard time" with arguments presented by Covidien plc (NYSE:COV) in its long-running patent spat with Applied Medical Resources over surgical trocars.
A jury trial is set for trial later this month in the latest patent spat over surgical trocars between Applied Medical Resources Corp. and Covidien plc, after a judge denies an AMR motion for summary judgment.
The latest in a series of lawsuits between Applied Medical Resources Corp. and Covidien plc (NYSE:COV) is slated to go before a jury later this month, after a federal judge in Texas denied AMR's motion for summary judgment in the case.
Covidien announces plans for a new research & development facility in Shanghai that's slated to open in July 2012.
Covidien (NYSE:COV) announced plans for a flagship research & development center in Shanghai.
The 100,000-square-foot facility, which should be fully operational by July 2012, will house two of the Mansfield, Mass.-based health product maker's emerging market units: Tailored products and breakthrough platforms.